Drug Profile
SDZ GPI 562
Alternative Names: GPI 562Latest Information Update: 19 Dec 2002
Price :
$50
*
At a glance
- Originator Novartis
- Class Antiplatelets; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis; Xenotransplant rejection
Most Recent Events
- 19 Dec 2002 No development reported - Phase-I for Thrombosis in USA (IV)
- 19 Dec 2002 No development reported - Phase-I for Thrombosis in USA (PO)
- 16 May 2001 No-Development-Reported for Xenotransplant rejection in USA (Unknown route)